OakChart

Amneal Pharmaceuticals Inc

AMRXHealthcare·Drug Manufacturers - Specialty & Generic·USA·Mid·NASD·Nov 11 • 7:00 AM ET

21.05-0.33 (-1.54%)
2026-11-11 14:22 CET
Market cap
7,446.57 USD m
Revenue, TTM
3,195.72 USD m
Net income, TTM
133.30 USD m
Free cash flow, TTM
30.87 USD m
EPS diluted, TTM
0.41
P/E
51.68
Compare

Price

AMRX against its 20, 50 and 200-day averages
2050200beatmiss
12.5015.0017.5020.004.1M8.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AMRXclose 21.0520-day 20.4550-day 19.55200-day 16.0221.05

2.9% under 21.68 on 2 Nov 2026. Last 15 sessions, 14.0% high to low

Profile

AMRX
52-week range, 94% of the way up
11.3921.68

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

IndexRUT
Employees8500
IPODec 19, 1995
Beta1.21
ATR, 14d0.81
Rel volume0.00
Short float7.27%
Insider own55.02%
Inst own43.63%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap7.33B
Enterprise Value10.55B
Income133.30M
Sales3.20B
Book/sh1.52
Cash/sh0.49
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees8500
IPODec 19, 1995

Ratios

P/E51.68
Forward P/E17.07
PEG0.81
P/S2.29
P/B13.80
P/C42.75
P/FCF237.58
EV/EBITDA14.68
EV/Sales3.30
Quick Ratio1.24
Current Ratio1.87
Debt/Eq6.18
LT Debt/Eq5.75
Option/ShortYes / Yes

Earnings

EPS (ttm)0.41
EPS next Y1.23
EPS next Q0.24
EPS this Y27.66%
EPS next Y16.40%
EPS next 5Y21.09%
EPS past 3/5Y- -18.36%
Sales past 3/5Y10.92% 8.66%
EPS Y/Y TTM2272.07%
Sales Y/Y TTM8.88%
EPS Q/Q-984.93%
Sales Q/Q9.96%
EarningsNov 03 BMO
EPS/Sales Surpr.9.52% 5.49%

Ownership

Insider Own55.02%
Insider Trans-0.23%
Inst Own43.63%
Inst Trans0.24%
ROA3.01%
ROE63.20%
ROIC3.71%
Gross Margin40.24%
Oper. Margin16.45%
Profit Margin4.17%
SMA202.92%
SMA507.65%
SMA20031.38%
Trades-

Technical

Shs Outstand348.37M
Shs Float156.65M
Short Float7.27%
Short Ratio3.62
Short Interest11.39M
52W High21.68 -2.91%
52W Low11.39 84.81%
Volatility5.55% 4.01%
ATR (14)0.81
RSI (14)57.15
Beta1.21
Rel Volume0.00
Avg Volume3.15M
Volume332

Performance

Perf Week5.51%
Perf Month7.56%
Perf Quarter21.89%
Perf Half Y69.90%
Perf YTD67.06%
Perf Year76.15%
Perf 3Y398.82%
Perf 5Y300.19%
Perf 10Y40.33%
Recom1.12
Target Price24.29
Prev Close21.38
Price21.05
Change %-1.54%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 23, 2026InitiatedOOppenheimerOutperform$27+28.3%
Sep 09, 2026InitiatedLLeerink PartnersOutperform$23+9.3%
Apr 17, 2026InitiatedUUBSBuy$19-9.7%
Dec 09, 2025InitiatedBBarclaysOverweight$15-28.7%
Jun 06, 2025InitiatedGGoldmanBuy$12-43.0%
Feb 24, 2025UpgradeJJP MorganNeutral → Overweight$9 → $12-43.0%
Sep 06, 2024UpgradeJJP MorganUnderweight → Neutral$9-57.2%
Apr 07, 2021ResumedRRBC Capital MktsSector Perform$5-76.2%
Mar 08, 2021UpgradeGGoldmanSell → Buy$4 → $6.50-69.1%
Dec 14, 2020UpgradeGGuggenheimNeutral → Buy$5.50-73.9%

Peers

Mkt cap
TickerCompanyMkt cap
TEVATeva- Pharmaceutical Industries Ltd50.24B
VTRSViatris Inc23.96B
RDYDr. Reddy's Laboratories Ltd ADR12.30B
ANIPANI Pharmaceuticals Inc1.63B
AMPHAmphastar Pharmaceuticals Inc1.24B
ALVOAlvotech1.93B
SUPNSupernus Inc5.97B
PRGOPerrigo Company plc2.33B
BHCBausch Health Companies Inc3.14B
OGNOrganon & Co3.64B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BUCHI J KEVINDirectorSep 11 '26Option Exercise14.4520,445295,43095,522Sep 14 04:10 PM
Kiely JohnDirectorAug 13 '26Sale17.6450,000882,000210,252Aug 14 04:29 PM
Shah NikitaExecutive Vice PresidentAug 12 '26Sale17.51146,4032,563,517253,390Aug 13 04:22 PM
Daly Jason B.EVP, Chief Legal OfficerAug 12 '26Sale17.40210,0003,654,00035,171Aug 13 04:21 PM
Daly Jason B.EVP, Chief Legal OfficerAug 11 '26Sale17.706,613117,050245,171Aug 13 04:21 PM
JOHN KIELYDirectorAug 13 '26Proposed Sale17.5950,000879,714Aug 13 04:15 PM
NIKITA SHAHOfficerAug 12 '26Proposed Sale17.47146,4032,556,975Aug 12 04:18 PM
JASON DALYOFFICERAug 11 '26Proposed Sale17.36210,0003,646,285Aug 12 04:11 PM
BUCHI J KEVINDirectorAug 11 '26Proposed Sale17.31168,5732,917,998Aug 11 12:32 PM
Autor Deborah M.DirectorMay 11 '26Sale12.9434,819450,55893,660May 12 04:10 PM
DEBORAH AUTORDIRECTORMay 11 '26Proposed Sale12.9434,819450,416May 11 06:56 PM
Nark Ted CDirectorNov 17 '25Sale11.7250,000586,000291,029Nov 19 04:21 PM
Nark Ted CDirectorNov 17 '25Proposed Sale11.8250,000591,250Nov 17 03:06 PM
Shah NikitaExecutive Vice PresidentNov 12 '25Option Exercise2.75131,856362,604278,259Nov 14 05:13 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.63B
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
VBVanguard Morningstar Small-Cap ETFAUM: 79.96B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.82B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B
XSMOInvesco S&P SmallCap Momentum ETFAUM: 2.75B
VXFVanguard Extended Market Index ETFAUM: 30.61B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.11B
IWNiShares Russell 2000 Value ETFAUM: 14.17B

News

latest 14 of 206
  • Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers (GlobeNewswire)
  • Amneal Beats And Raises Again, But Cash Flow, Leverage, And A Pulled-Forward Quarter Temper The Story (Earnings Whispers)
  • Amneal Pharmaceuticals Raises 2026 Guidance After Q3 Revenue Climbs 10% to $862.7 Million (InvestorsHub)
  • Amneal Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Amneal's Q3 Report Tests Whether Its Guidance-Raising Streak Can Outrun A Modest Growth Bar (Earnings Whispers)
  • Loading…
  • Amneal to Report Third Quarter 2026 Results on November 3, 2026 (GlobeNewswire)
  • Ipsen Shares Fall After Early Launch of U.S. Generic Rival (The Wall Street Journal) +7.75%
  • Amneal Announces FDA Approval and Launch of Lanreotide Injection (GlobeNewswire)
  • Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader (GlobeNewswire)
  • Amneal Pharmaceuticals Inc (AMRX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com)
  • Amneal Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations (GlobeNewswire)
  • Amneal to Report Second Quarter 2026 Results on July 30, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-030.2600.237-0.060862.68817.777
2026Q22026-07-300.3000.2230.176796.2768.214
2026Q12026-04-220.2700.1690.189722.52719.666
2025Q42026-02-270.2100.1840.107814.32807.355
2025Q32025-10-300.1700.1380.007784.51773.864
2025Q22025-08-050.2500.1750.070724.51744.564
2025Q12025-05-020.2100.1470.038695.42714.783
2024Q42025-02-280.1200.153-0.100730.52708.074
2024Q32024-11-080.1600.134-0.001702.47693.784
2024Q22024-08-090.1600.1480.019701.78657.524
2024Q12024-05-030.1400.092-0.298659.196195
2023Q42024-03-010.1400.090-0.405616.98634.965
2023Q32023-11-070.1900.1270.061620.04602.65
2023Q22023-08-040.1900.0990.077599.05565.145
2023Q12023-05-050.1200.096-0.046557.54539.145
2022Q42023-03-020.2300.208-0.029609.76579.837

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY0.9800.897-0.1641,8611,841
2019FY0.3500.321-2.7401,6261,610
2020FY0.6300.6230.6121,9931,990
2021FY0.8500.8760.0702,0942,092
2022FY0.6800.655-0.8612,2122,183
2023FY0.6400.592-0.4772,3942,412
2024FY0.5800.613-0.3782,7942,770
2025FY0.8300.8000.2203,0193,012
2026FY-1.060--3,211
2027FY-1.233--3,507
2028FY-1.474--3,880
2029FY-1.810--4,532

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-08641838.21812.12857
2026Q4S2026-11-05651838.21812.12857
2026Q4S2026-11-03641834.52812.12857
2026Q4S2026-10-28620825.24803.1843.7
2026Q4S2026-10-21610823.84803.1843.7
2026Q4S2026-10-13610824.78803.1843.7
2026Q4S2026-10-05630824.78803.1843.7
2026Q4S2026-09-22630824.98803.69843.7
2026Q4S2026-09-08530822.46803.69843.7
2026Q4S2026-08-25430827803.69843.7
2026Q4S2026-08-13420822.09803.69843.7
2026Q4S2026-07-31320824.67803.69843.7
2026Q4S2026-07-30320822.79803.69843.7
2026Q4S2026-07-14301804.59779.29820.98

Estimate history

EPS, annual0-0.164-2.740.6120.07-0.861-0.477-0.3780.2220.4073
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.001-0.10.0380.070.0070.1070.1890.176-0.065
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1033.6541662.9911626.3731992.5232093.6692212.3042393.6072793.9573018.763195.72
Period201720182019202020212022202320242025TTM
Sales, quarterly702.468730.518695.42724.508784.513814.319722.519796.197862.684
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual189127.376147.07147.674149.413151.49306.565309.881314.565348.368
Period201720182019202020212022202320242025MRQ
Shares, quarterly309.77309.881313.385314.043314.311314.565318.998319.33348.368
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3,195.723,018.762,793.962,393.612,212.302,093.671,992.521,626.371,662.99
Cost of Goods Sold Incl. D&A1,909.791,882.671,773.521,536.941,416.481,302.001,329.551,147.21937.59
Gross Profit1,285.931,136.091,020.44856.66795.82791.66662.97479.16725.40
Selling, General and Administrative Excl. Other755.69713.00667.15593.62595.39567.35506.66477.65424.62
Research and Development182.00186.18190.71163.95195.69201.85179.93188.05194.19
Other Operating Expense4.570.000.000.000.000.000.000.000.00
Operating Income525.67423.09353.29263.04200.43224.31156.311.51300.78
Interest Expense223.55241.09258.60210.63158.38136.32146.00168.21143.57
Unusual Expense64.4865.60103.96100.61299.6171.6065.1657.31340.12
Net Income Before Taxes221.46139.21-55.01-40.27-248.1331.37-35.78-220.24-202.72
Income Taxes11.9611.2818.868.456.6611.20-104.36383.33-1.42
Consolidated Net Income209.49127.93-73.88-48.72-254.7920.1768.58-603.57-52.50
Net Income From Continuing Operations133.3072.06-116.89-83.99-129.9910.6291.06-361.92-20.92
Net Income133.3072.06-116.89-83.99-129.9910.6291.06-361.92-20.92
EPS (Recurring)0.530.36-0.14-0.080.530.400.92-2.441.71
EPS (Basic, Before Extraordinaries)0.420.23-0.38-0.48-0.860.070.62-2.74-0.16
EPS (Diluted)0.410.22-0.38-0.48-0.860.070.61-2.74-0.16
EBITDA719.14646.66589.48492.44440.61457.72396.20208.75438.18
Non-Operating Income (Expense)-16.1722.81-45.747.939.4314.9719.063.76-19.81
Other After Tax Adjustments0.000.000.000.000.000.000.000.00148.81
Stock Option Compensation Expense29.9625.2421.9421.1925.1620.7415.1515.836.45
Price To Earnings Ratio52.4952.49-95.89-69.527.43--
Price To Sales Ratio2.121.360.880.450.140.350.340.391.04
Gross Margin40.2437.6336.5235.7935.9737.8133.2729.4643.62
Operating Margin16.4514.0212.6410.999.0610.717.850.0918.09
Net Margin4.172.39-4.18-3.51-5.880.514.57-22.25-1.26
Shares Outstanding348.37314.56309.88306.56151.49149.41147.67147.07127.38
Market Capitalization7,446.577,446.572,453.961,860.72301.44715.49674.66646.341,722.46

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue862.68796.20722.52814.32784.51724.51695.42730.52
Cost of Goods Sold Incl. D&A528.57461.69402.41517.13510.54438.25439.53467.64
Gross Profit334.12334.51320.11297.19273.97286.25255.89262.87
Selling, General and Administrative Excl. Other208.02187.74177.24182.69201.17172.23158.33182.95
Research and Development68.3739.0238.3836.2363.3547.9640.0454.27
Other Operating Expense4.570.000.000.000.000.000.000.00
Operating Income121.53146.77142.87114.5072.81114.0297.5679.92
Interest Expense58.9155.0453.3656.2462.8165.1056.9461.66
Unusual Expense32.1718.3011.552.4733.952.652.344.13
Net Income Before Taxes15.0670.9980.1855.23-5.2251.7137.49-15.32
Income Taxes2.751.382.185.66-23.3616.1012.875.42
Consolidated Net Income12.3169.6178.0049.5718.1335.6124.62-20.74
Net Income From Continuing Operations-21.7057.6662.2635.082.3722.4212.20-31.08
Net Income-21.7057.6662.2635.082.3722.4212.20-31.08
EPS (Recurring)0.000.210.210.110.080.080.04-0.09
EPS (Basic, Before Extraordinaries)-0.060.180.200.110.010.070.04-0.10
EPS (Diluted)-0.060.180.190.110.010.070.04-0.10
EBITDA174.78194.57186.06163.73126.88174.14157.72146.05
Non-Operating Income (Expense)-15.39-2.442.22-0.5618.735.44-0.80-29.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.318.216.966.486.496.545.735.70
Price To Earnings Ratio52.4946.4156.14887.321,564.06---
Price To Sales Ratio2.121.821.341.371.110.910.960.88
Gross Margin38.7342.0144.3136.5034.9239.5136.8035.98
Operating Margin14.0918.4319.7714.069.2815.7414.0310.94
Net Margin-2.517.248.624.310.303.091.75-4.25
Shares Outstanding348.37319.33319.00314.56314.31314.04313.38309.88
Market Capitalization7,446.575,527.623,910.843,960.973,143.932,535.572,626.142,453.96

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments310.87118.4299.1135.23256.74347.12152.82218.7877.92
Short Term Receivables939.87808.56645.66796.91727.74674.21635.89565.32382.73
Inventories606.30612.45581.38530.74489.39490.65381.07457.22284.04
Other Current Assets54.1348.3751.7148.9546.2439.5540.4345.3227.25
Total Current Assets1,911.181,587.811,377.861,411.821,520.111,551.541,210.211,286.64771.93
Net Property, Plant & Equipment550.33523.69550.14589.36639.00604.71620.60544.15486.76
Total Investments and Advances7.8235.9237.0985.590.000.0016.370.000.00
Long-Term Note Receivable--------1E-05
Intangible Assets1,158.971,329.811,489.051,694.951,759.941,827.441,802.262,081.2071.04
Deferred Tax Assets------0.00373.160.90
Other Assets49.9824.2118.4317.6320.6122.3416.4567.5911.26
Total Assets3,678.283,501.453,472.573,799.343,939.664,006.033,665.894,352.741,341.89
Short Term Debt Incl. Current Port. of LT Debt21.58340.25227.62104.6446.0457.6836.9521.7189.48
Accounts Payable254.67258.69143.57165.98131.08153.14103.02114.8570.01
Income Tax Payable---0.362.525.548.73--
Other Current Liabilities605.39530.83475.40481.82497.60460.54401.70417.29137.39
Total Current Liabilities881.631,129.77846.60752.80677.24676.90550.41553.85296.88
Long Term Debt2,667.472,252.882,522.902,740.502,830.022,887.452,729.112,669.681,395.26
Provision for Risks Charges0.001.250.500.563.180.000.000.000.00
Deferred Tax Liabilities------0.001.182.49
Other Liabilities123.21162.0841.2796.5545.3484.9539.58231.6622.84
Total Liabilities3,672.323,545.983,411.263,590.413,555.783,649.303,319.103,456.371,717.47
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-70.79-109.2719.78298.42360.34303.27232.01504.75-385.74
Total Shareholders Equity-70.79-109.2719.78298.42360.34303.27232.01504.75-385.74
Accumulated Minority Interest76.7664.7341.52-89.4923.5453.47114.78391.6110.16
Total Equity5.96-44.5461.30208.93383.88356.74346.79896.36-375.58
Total Liabilities & Stockholders Equity3,678.283,501.453,472.573,799.343,939.664,006.033,665.894,352.741,341.89
Book Value Per Share-0.23-0.350.061.972.412.051.583.96-2.04
Tangible Book Value Per Share-3.91-4.64-4.79-9.22-9.37-10.32-10.68-12.38-2.42
Full-Time Employees8,5008,3007,8507,7507,0006,0005,5006,000-
Price to Book Ratio14.02-26.262.831.011.992.233.063.413.52
Return on Assets2.01-3.35-2.31-3.360.272.37-9.03-0.960.00
Return on Equity---52.79-39.463.2034.02-98.25-8.290.00
Return on Invested Capital2.77-5.45-3.30-4.280.332.85-12.22-0.660.00
Quick Ratio1.480.860.941.171.521.571.511.501.64
Current Ratio2.171.411.631.882.242.292.202.322.60

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income209.49127.93-73.88-48.72-254.7920.1768.58-603.57-201.30
Depreciation193.48223.57236.19229.40240.18233.41235.39207.24137.40
Other Funds (Non Cash)193.20193.00136.7849.67138.00121.84136.35146.54316.56
Funds from Operations596.17544.51299.10230.35123.38375.41440.32121.92243.22
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-423.10-204.52-4.07-47.19-59.95-133.59-61.32-120.227.01
Cash from Operating Activities173.08339.99295.03183.1663.44241.82379.001.71250.23
Capital Expenditures-241.81-114.36-74.99-69.19-90.59-49.43-66.19-97.43-97.09
Net Assets From Acquisitions-421.450.000.000.00-86.44-146.54-254.66-3.54-336.41
Sale of Fixed Assets and Businesses0.712.0911.990.000.005.000.0034.8325.34
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-3.210.000.000.00
Other Sources0.000.000.000.001.000.000.0043.020.00
Cash from Investing Activities-662.54-112.26-63.00-69.19-176.03-194.18-320.85-23.12-408.15
Cash Dividends Paid0.000.000.000.000.000.000.000.00-183.00
Change in Capital Stock1.071.961.150.450.660.850.321.4031.90
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.071.961.150.450.660.850.321.4031.90
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.0028.10
Issuance or Reduction of Debt, Net510.5626.27-185.1222.65-38.27-79.18142.99-29.27541.05
Change in Long Term Debt510.5626.27-185.1222.65-38.27-78.18142.99-29.27633.09
Issuance of Long Term Debt809.852,837.7848.00436.7385.000.00180.000.001,325.38
Reduction of Long Term Debt-299.30-2,811.51-233.12-414.08-123.27-78.18-37.01-29.27-692.29
Net Financing Active Other Cash Flow-78.31-59.76-27.76-73.26-65.62-59.80-8.20-14.42-90.50
Other Financing Activities Uses-79.61-66.13-27.76-73.26-65.62-59.80-8.20-14.42-90.50
Cash from Financing Activities433.32-31.53-211.72-50.16-103.23-138.12135.11-42.29299.45
Exchange Rate Effect-2.01-1.68-1.000.07-5.680.101.04-2.25-0.67
Net Change in Cash-58.15194.5219.3163.88-221.51-90.38194.30-65.96140.86
Free Cash Flow30.87241.15234.69136.3614.64194.09317.17-45.48167.14
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow219.0116.9710.437.8420.513.752.15--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00371.72-9.44

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments171.57136.28201.83310.87235.9881.19
Short Term Receivables1,144.501,082.63902.65939.87924.14849.26
Inventories707.96677.95641.62606.30614.50608.97
Other Current Assets70.9950.1751.8154.1363.8745.27
Total Current Assets2,095.021,947.031,797.911,911.181,838.481,584.69
Net Property, Plant & Equipment725.67567.32558.76550.33538.05546.29
Total Investments and Advances42.4519.5512.737.827.6018.92
Intangible Assets2,323.731,181.331,128.671,158.971,183.881,246.95
Other Assets80.3561.1242.1549.9831.8625.93
Total Assets5,267.223,776.353,540.223,678.283,599.873,422.79
Short Term Debt Incl. Current Port. of LT Debt225.56121.4221.4821.5821.47335.41
Accounts Payable283.66244.23227.68254.67266.36205.81
Other Current Liabilities610.62517.53478.89605.39574.28565.92
Total Current Liabilities1,119.84883.19728.05881.63862.111,107.13
Long Term Debt3,057.342,670.342,675.002,667.472,664.252,246.49
Provision for Risks Charges0.000.000.000.000.220.52
Other Liabilities449.34105.8497.22123.21115.47115.37
Total Liabilities4,626.513,659.373,500.283,672.323,642.053,469.52
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity531.2633.02-45.41-70.79-109.46-112.12
Total Shareholders Equity531.2633.02-45.41-70.79-109.46-112.12
Accumulated Minority Interest109.4583.9685.3576.7667.2865.39
Total Equity640.71116.9839.945.96-42.17-46.73
Total Liabilities & Stockholders Equity5,267.223,776.353,540.223,678.283,599.873,422.79
Book Value Per Share1.520.10-0.14-0.23-0.35-0.36
Tangible Book Value Per Share-5.15-3.60-3.68-3.91-4.11-4.33
Full-Time Employees---8,500--
Price to Book Ratio14.02-121.59-55.23-36.18-28.04-19.26
Return on Assets3.014.373.542.010.170.10
Return on Equity63.20-----
Return on Invested Capital-0.602.132.371.350.091.05
Quick Ratio1.241.441.591.481.420.88
Current Ratio1.872.202.472.172.131.43

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income12.3169.6178.0049.5718.1335.61
Depreciation53.2647.8043.1949.2354.0760.11
Other Funds (Non Cash)56.3852.8540.1743.8096.9823.20
Funds from Operations121.95170.26161.36142.60169.19118.93
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-29.21-191.51-190.08-12.29-50.74-35.11
Cash from Operating Activities92.73-21.24-28.73130.31118.4583.82
Capital Expenditures-51.19-122.74-21.71-46.17-22.46-27.40
Net Assets From Acquisitions-421.05-0.400.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.710.000.85
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-472.23-123.14-21.71-45.45-22.46-26.55
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.440.040.040.550.650.69
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.440.040.040.550.650.69
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net429.0493.81-6.17-6.1267.21-17.29
Change in Long Term Debt429.0493.81-6.17-6.1267.21-17.29
Issuance of Long Term Debt575.18100.00134.670.002,619.780.00
Reduction of Long Term Debt-146.15-6.18-140.84-6.12-2,552.56-17.29
Net Financing Active Other Cash Flow-8.72-14.10-50.94-4.55-8.42-25.08
Other Financing Activities Uses-8.72-14.10-51.45-5.34-14.00-25.08
Cash from Financing Activities420.7579.76-57.07-10.1259.44-41.69
Exchange Rate Effect-0.62-0.16-1.02-0.21-0.69-0.31
Net Change in Cash40.63-64.79-108.5374.53154.7415.28
Free Cash Flow53.15-66.84-42.5987.15103.4057.32
Price to Free Cash Flow219.0170.0119.9217.1413.039.63

Revenue breakdown

United States2024: 2.79B 2025: 3.02B
Affordable Medicines2024: 1.69B 2025: 1.75B
AvKARE2024: 662.95M 2025: 744.73M
Specialty2024: 445.75M 2025: 528.51M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.27%11.4M156.7M2.82M
2026-10-159.79%14.1M143.6M2.44M
2026-09-307.85%11.3M143.6M2.10M
2026-09-157.86%11.3M143.6M1.92M
2026-08-317.36%10.6M143.6M1.97M
2026-08-146.63%9.5M143.4M2.01M
2026-07-315.09%8.3M163.6M1.93M
2026-07-154.96%8.1M163.6M1.92M
2026-06-304.79%7.8M163.4M1.85M
2026-06-155.07%7.9M156.0M1.77M
2026-05-294.82%7.5M156.3M1.82M
2026-05-155.10%8.0M156.3M1.87M
2026-04-307.45%11.5M154.4M1.97M
2026-04-155.54%8.6M154.4M2.61M
2026-03-314.58%7.2M156.9M2.63M
2026-03-136.91%10.8M156.9M2.57M
2026-02-276.32%9.9M156.9M2.48M
2026-02-136.76%10.6M156.8M2.41M
2026-01-308.09%12.7M156.8M2.44M
2026-01-154.32%6.8M156.8M1.75M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5017.0020.900.0019.9560.000.000.984-0.0710.001
call5.0014.5018.400.0011.3180.000.000.971-0.0770.002
call7.5012.0015.900.008.1530.000.000.958-0.0780.003
call10.009.5013.700.006.9600.000.000.943-0.0750.004
call12.507.0011.000.004.8540.000.000.924-0.0710.005
call15.004.508.500.003.7320.000.000.898-0.0660.006
call17.502.056.002.802.9712.000.000.850-0.0570.008
call20.000.003.801.552.26564.000.000.694-0.0620.012
call22.500.100.400.400.5422304.000.391-0.0610.013
call25.000.000.100.011.0932.000.000.202-0.0540.010
call30.000.001.950.001.2310.000.000.058-0.0260.004
put2.500.002.150.0023.2110.000.00-0.007-0.0730.001
put5.000.002.150.0012.0320.000.00-0.043-0.1890.003
put7.500.002.150.008.6260.000.00-0.075-0.2120.005
put10.000.002.150.006.5800.000.00-0.109-0.2130.007
put12.500.002.150.005.1030.000.00-0.149-0.2050.008
put15.000.002.150.051.9791.000.00-0.104-0.0640.006
put17.500.002.150.301.32475.000.00-0.150-0.0550.008
put20.000.002.500.800.6941060.00-0.306-0.0600.012
put22.500.003.303.551.9005.000.00-0.609-0.0580.013
put25.001.805.500.002.2610.000.00-0.907-0.0180.006
put30.006.8010.508.703.0921.000.00-0.942-0.0220.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-238-K/A2026-08-10SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-03S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-12SCHEDULE 13D/ASEC
2026-08-12SCHEDULE 13D/ASEC
2026-08-12SCHEDULE 13D/ASEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-318-KCurrent report2026-07-31SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-29DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08007.22M4
2026-070000
2026-060000
2026-0500450.56K1
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11002.16M2

Institutional holders

Manager% owned
BlackRock, Inc.8.32%
TPG GP A, LLC3.86%
VANGUARD PORTFOLIO MANAGEMENT LLC3.80%
Rubric Capital Management LP3.18%
VANGUARD CAPITAL MANAGEMENT LLC2.41%
STATE STREET CORP2.30%
DIMENSIONAL FUND ADVISORS LP1.82%
GEODE CAPITAL MANAGEMENT, LLC1.43%
Nantahala Capital Management, LLC1.42%
MORGAN STANLEY1.29%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF3.25%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.74%
iShares Russell 2000 ETF1.37%
VANGUARD SMALL-CAP INDEX FUND1.26%
VANGUARD SMALL-CAP VALUE INDEX FUND0.80%
VANGUARD EXTENDED MARKET INDEX FUND0.62%
Invesco S&P SmallCap Momentum ETF0.58%
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF0.50%
U.S. SMALL CAP PORTFOLIO0.39%
College Retirement Equities Fund - Total Global Stock Account0.37%

OakChart. AMRX. Cached 15 minutes.